PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Texas Instruments Incorporated (TXN)
205.980.01 (0.00%)
205.24 - 207.41
139.95 - 221.69
4.54M / 6.54M (Avg.)
37.59 | 5.48
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
17.79%
Positive revenue growth while AVGO is negative. John Neff might see a notable competitive edge here.
39.45%
Positive gross profit growth while AVGO is negative. John Neff would see a clear operational edge over the competitor.
272.17%
Positive EBIT growth while AVGO is negative. John Neff might see a substantial edge in operational management.
3330.00%
Positive operating income growth while AVGO is negative. John Neff might view this as a competitive edge in operations.
1429.41%
Positive net income growth while AVGO is negative. John Neff might see a big relative performance advantage.
2000.00%
Positive EPS growth while AVGO is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.
1900.00%
Positive diluted EPS growth while AVGO is negative. John Neff might view this as a strong relative advantage in controlling dilution.
-0.63%
Share reduction while AVGO is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-0.39%
Both reduce diluted shares. Martin Whitman would review each firm’s ability to continue repurchases and manage option issuance.
-0.80%
Dividend reduction while AVGO stands at 0.00%. Joel Greenblatt would question the firm’s cash flow stability or capital allocation decisions.
121.91%
OCF growth under 50% of AVGO's 1750.00%. Michael Burry might suspect questionable revenue recognition or rising costs.
144.71%
FCF growth under 50% of AVGO's 431.25%. Michael Burry would suspect weaker operating efficiencies or heavier capex burdens.
29.78%
10Y CAGR of 29.78% while AVGO is zero. Bruce Berkowitz would see if incremental growth can widen into a significant edge.
5.55%
5Y CAGR of 5.55% while AVGO is zero. Bruce Berkowitz would see if small improvements can scale into a larger advantage.
-18.54%
Negative 3Y CAGR while AVGO stands at 0.00%. Joel Greenblatt would look for missteps or fading competitiveness that hurt sales.
128.04%
OCF/share CAGR of 128.04% while AVGO is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
53.26%
OCF/share CAGR of 53.26% while AVGO is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
6.84%
3Y OCF/share CAGR of 6.84% while AVGO is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
-0.33%
Negative 10Y net income/share CAGR while AVGO is at 0.00%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-17.92%
Negative 5Y net income/share CAGR while AVGO is 0.00%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-86.65%
Negative 3Y CAGR while AVGO is 0.00%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
73.41%
Equity/share CAGR of 73.41% while AVGO is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
3.13%
Equity/share CAGR of 3.13% while AVGO is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
-11.69%
Negative 3Y equity/share growth while AVGO is at 0.00%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
417.19%
Dividend/share CAGR of 417.19% while AVGO is zero. Bruce Berkowitz sees a slight advantage in stepping up payouts steadily.
423.04%
Dividend/share CAGR of 423.04% while AVGO is zero. Bruce Berkowitz sees a minor advantage in stepping up distributions, even modestly.
262.50%
3Y dividend/share CAGR of 262.50% while AVGO is zero. Bruce Berkowitz sees a minor positive difference that could attract dividend-focused investors.
10.58%
AR growth of 10.58% while AVGO is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
-3.19%
Inventory is declining while AVGO stands at 0.00%. Joel Greenblatt sees potential cost and margin benefits if sales hold up.
-0.09%
Negative asset growth while AVGO invests at 0.00%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
0.66%
BV/share growth of 0.66% while AVGO is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
-4.40%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
7.21%
SG&A growth well above AVGO's 5.00%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.